Stroke: antithrombin versus antiplatelet therapy

Bibliography

• HARKER LA: Therapeutic inhibition of platelet function in stroke. Cerebrovasc. Dis. (1998) 8\(Suppl. 5):8–18.
   Google Scholar
• •Excellent review of potential antiplatelet strategies and their mechanisms.
   Google Scholar
• XI G, KEEP RF, HUA Y, XIANG J, HOFF JT: Attenuation ofthrombin-induced brain edema by cerebral thrombin preconditioning. Stroke (1999) 30:1247–1255.
   PubMed Web of Science ®Google Scholar
• KARIO K, MATSUO T, HOSHIDE S, UMEDA Y, SHIMADA K:Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease an mr spectrocopy study. Stroke (1999) 30:1033–1037.
   PubMed Web of Science ®Google Scholar
• SAMAMA MM, DESNOYERS PC, CONARD J, BOUSSER MG:Acute ischemic stroke and heparin treatments. Thromb. Haemosi (1997) 78 (Suppl. 0:173–179. FENTON JW, OFOSU FA, BREZNIAK DV, HASSOUNA HI: Thrombin and antithrombotics. Semin. Thromb. HemosL (1998) 24 (Suppl. 2)87–90. Good overview of the basic science of antithrombin therapies and how they can be applied clinically. GENSINI RF, COMEGLIO M, FALAI M: Advances in antithrombotic therapy of acute myocardial infarc-tion. Am. Heart J. (1999) 138 (Suppl. 2):S171–S176.
   Google Scholar
• YARDUMIAN DA, MACKIE IJ, MACHIN SJ: Laboratoryinvestigation of platelet function: a review of method-ology. J. Clin. Pathol (1986) 39:701–712.
   PubMed Web of Science ®Google Scholar
• GARTNER TK, BENNETT JS: The tetrapeptide analogueof the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J. Biol. Chem. (1985) 160:11891–11894.
   Google Scholar
• FERGUSON JJ,WALY HM, WILSON JM: Fundamentals ofcoagulation and glycoprotein 11b/111a receptor inhibi-tion. Eur. Heart J. (1998) 19(D):D3–D9.
   Google Scholar
• •Succinct overview of antiplatelet and antithrombin therapy from basic science to clinical application.
   Google Scholar
• SHERMAN D: Heparin and heparinoids in stroke.
   Google Scholar
• Neurology (1998) 51 (S3):S56–S58.
   Google Scholar
• •Timely clinically-related summary of antithrombin trials to date.
   Google Scholar
• SANDERCOCK P, GUBITZ G, COUNSELL C, SIGNORINI D: Immediate anticoagulant therapy for acute ischaemic stroke part 1: A systematic review of 21 randomised trials of anticoagulant vs. control, including 23,374 patients. 24th American Heart Association International Conference on Stroke and Cerebral Circulation. Nashville, TN, USA Stroke (1999) 30:248.
   Google Scholar
• HIRSH J, DALEN JE, DEYKIN D et al.: Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest (1 9 9 5) 108 (S1):231S–246S.
   Google Scholar
• ADAMS HP, BENDIXEN BH, LEIRA E et al.: Antithrom-botic treatment of ischemic stroke among patients with occlusion or severe stenosis on the internal carotid artery. Neurology (1999) 53:122–125.
   PubMed Web of Science ®Google Scholar
• HARKER LA, HANSON SR, KELLY AB: Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb. HaemosL (1997) 78:736–741.
   PubMed Web of Science ®Google Scholar
• LOSCALZO J: Thrombin inhibitors in fibrinolysis. Circulation (1996) 94:863–865
   PubMed Web of Science ®Google Scholar
• KERNS RT, KINI RM, STEFANSSON S, EVANS HJ: Targeting of venom phospholipases: the strongly anticoagulant phospholipase A(2) from Naja Nigricollis venom binds to coagulation Factor Xa to inhibit the prothrombinase complex. Arch. Biochem. Biophys. (1999) 369\(Suppl. 0:107–113.
   Google Scholar
• MARKLAND FS: Snake venoms and the hemostatic system. American Society of Hematology-40th Annual Meeting. Miami, Fl, USA, December 1998. Toxicon (1998) 36(12)1749–1800.
   Google Scholar
• STANSSENS P, BURGUM PW, GANSEMANS Y etal.: Antico-agulant repertoire of the hookworm Ancylostoma caninum. Proc. Natl. Acad. Sci. USA (1996) 93 (Suppl. 5):2149–2154.
   Google Scholar
• SENIOR K: Taking the bite out of snake venoms. Lancet(1999) 3 5 3(9168):1946.
   Google Scholar
• KEMP KV, JOCHMANS K, VAN TUSSENBROEK F, DEBRUYNE H, VAN DEN BRANDE P: Desmin (a low molecular weight dermatan sulphate) versus heparin in the treatment of patients with deep venous thrombosis. Eur. J. Clin. Pharmacol. (1998) 54:133–139.
   PubMed Web of Science ®Google Scholar
• SITKO GR, RAMJIT DR, STABILITO II, LEHMAN D, LYNCHJJ, VALASUK GP: Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with selective Factor Xa inhibitor, tick anticoagulant peptide. comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation (1992) 85:805–815.
   Google Scholar
• APITZ-CASTRO R, BEGUIN S, TABLANTE A, BARTOLI F, HOLT JC, HEMKER HC Purification and partial charcterisation of draculin, the anticoagulant factor present in the saliva of vampire bats (Desmodus rotundus). Thromb. HaemosL (1995) 73 (Suppl. 0:94–100.
   Google Scholar
• YAMAZAKI M, ASAKURA H, AOSHIMA K et al.: Effects of DX-9065a and orally active, newly synthetized and specific inhibitor of Factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb. HaemosL (1994) 72 (Suppl. 3):393–396.
   Google Scholar
• Beyond Heparin-CHI. Conference Novel Anticoagulants and Emerging Applications. San Diego, CA, USA (27–29 May 1999).
   Google Scholar
• CHI L, ROGERS KL, UPRICHARD ACG, GALLAGHER KP: The therapeutic potential of novel anticoagulants. Exp. Opin. Invest. Drugs (1997) 6(10:1591–1622.
   PubMedGoogle Scholar
• SEALE L, FINNEY S, SAWYER RT, WALLIS RB: Tridegin, a novel peptidic inhibitor of factor xiiIa from the leech, Haementeria Ghilianii, enhances fibrinolysis in vitro. Thromb. HaemosL (1997) 77 (Suppl. 5):959–963.
   Google Scholar
• International Society on Thrombosis and Haemostasis-17th Congress. Washington DC, USA (14–21 August 1999).
   Google Scholar
• NEUHAUS KL: New antithrombotic and antiplatelet treatment. Heart (1999) 82:8–11.
   Web of Science ®Google Scholar
• FEINBERG W: Anticoagulation for prevention of stroke. Neurology (1998) 51(3):520–522.
   PubMed Web of Science ®Google Scholar
• •Excellent clinical review of the role of anticoagulant therapy for stroke.
   Google Scholar
• GORELICK PB, SACCO RL, ALBERTS M et al.: Prevention of a first stroke. JAM4(1999) 281 (Suppl. 12):1112–1120.
   Google Scholar
• ANONYMOUS: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in anal fibrillation III randomized clinical trial. Lancet (1996) 348:633–638.
   PubMed Web of Science ®Google Scholar
• ••Pivotal study examining the role of aspirin and anticoagu-lant therapy for high risk NVAF patients.
   Google Scholar
• BENAVENTE 0, HART R: Warfarin vs. aspirin for prevention of stroke in nonvalvular areil fibrillation: meta-analysis. 24th American Heart Association International Conference on Stoke and Cerebral Circulation. Nashville, TN, USA Stroke (1999) 30:241.
   Google Scholar
• SHERMAN DG: Defibrinogenation with Viprinex (Ancrod) for the treatment of acute, ischemic stroke. Stroke (1999) 30:234.
   Web of Science ®Google Scholar
• VERSTRAETE M: Risk factors, interventions andtherapeutic agents in the prevention of atherosclerosis-related ischaemic diseases. Drugs (1991) 42\(Suppl. 5):22–38.
   Google Scholar
• SECOND INTERNATION STUDY OF INFARCT SURVIVALCOLLABORATIVE GROUP (ISIS-2): Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet (1988) 2:349–60.
   PubMed Web of Science ®Google Scholar
• •Landmark study defining the role of aspirin and thrombolytics both as monotherapies and as combination therapy.
   Google Scholar
• AEBERHARD EE, HENDERSON SA, ARABOLOS NS et al. Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. BioChem. Biophy. Res. Commun. (1 9 9 5) 208:1053-1059.
   Google Scholar
• KOPP E, GHOSH S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science (1994) 265:956–959.
   PubMed Web of Science ®Google Scholar
• RATNATUNGA CP, EDMONDSON SF, REES GM, KOVACS IB: High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation (1992) 85:1077–1082.
   PubMed Web of Science ®Google Scholar
• RIEPE MW, KASISCHKE K, RAUPACH A: Acetylsalicylic acid increases tolerance against hypoxic and chemical hypoxia. Stroke (1997) 28:2006–2011.
   PubMed Web of Science ®Google Scholar
• VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature - New Biology (1971) 31:232–235.
   Google Scholar
• •Of historical interest in defining relating aspirin's efficacy to inhibition of prostaglandin synthesis.
   Google Scholar
• FITZGERALD GA, OATES JA, HAWIGER J et al.: Endoge-nous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest. (1983) 71:676–688.
   PubMed Web of Science ®Google Scholar
• HSU CY, FAUGHT RE Jr, FURLAN AJ et al.: Intravenousprostacyclin in acute nonhemorrhagic stroke: a placebo-controlled double-blind trial. Stroke (1987) 18:352–358.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, FREHEL D, VALLEE E et al.: Clopidogrel, anovel antiplatelet and antithrombotic agent. Cardio-vasc. Drug Rev. (1993) 11(2):180–198.
   Web of Science ®Google Scholar
• MULTICENTRE ACUTE STROKE TRIAL-ITALY GROUP (MAST-I): Randomized controlled trial of streptoki-nase, aspirin and combination of both in treatment of acute ischaemic stroke. Lancet (1995) 346:1509–1514.
   PubMed Web of Science ®Google Scholar
• ••The only randomised, prospective placebo-controlled trialto date examining the effect of aspirin within 6 h of ischaemic stroke.
   Google Scholar
• INTERNATIONAL STROKE TRIAL COLLABORATIVE GROUP (1ST): A randomized trial of aspirin, subcuta-neous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet (1 9 9 7) 349:1569–1581 •Landmark study examining the efficacy of aspirin in acuteischaemic stroke.
   Google Scholar
• CHINESE ACUTE STROKE TRIAL COLLABORATIVE GROUP (CAST): Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet (1997) 349: 1641-1649.
   Google Scholar
• ••Landmark study examining the efficacy of aspirin in acuteischaemic stroke.
   Google Scholar
• LEFKOVITS J, PLOW EF, TOPOL EJ: Platelet glycoproteinIlb/Ifia receptors in cardiovascular medicine. N Engl. J. Med. (1995) 332:1553–1559.
   PubMed Web of Science ®Google Scholar
• ADAMS H: Preliminary safety report of an ongoingdose-escalation trial of abciximab in acute ischemic stroke. 24th American Heart Association International Conference on Stroke and Cerebral Circulation. Nashville, TN,USA Stroke (1999) 30:244.
   Google Scholar
• MICKELSON JK, ALT MN, KLEIMAN NS eta].: Chimeric 7E3fab (ReoPro) decreases detectable CD1 lb on neutro-phils from patients undergoing coronary angioplasty. J. Am. Coll Cardiol. (1999) 33:97–106.
   Google Scholar
• BEDNAR MM, WRIGHT SD, RAYMOND-RUSSELL SJ, KOHUT JJ, GROSS CE: IB4, a monoclonal antibody against the CD18 leukocyte adhesion protein, reduces intracranial pressure following thromboembolic stroke in the rabbit. Neurological Res. (1996) 18:171–175.
   PubMed Web of Science ®Google Scholar
• CHEN J, WEINSTEIN PR, GRAHAM SH: Attenuation of postischemic brain hypoperfusion and reperfusion injury by the cyclooxygenase-lipoxygenase inhibitor BW755C. J. Neurol. (1995) 83:99–104.
   Google Scholar
• BEDNAR MM, GROSS CE, BLAZY M, FALCK JR: Antineu-trophil strategies. Neurology (1997) 49 (Suppl. 4):S20–S22.
   Google Scholar
• MULERO JJ, YEUNG G, NELKEN ST, FORD JE: CD39-L4 is a secreted human apyrase, specific for the hydrolysis of nucleoside diphosphates. J. Biol. Chem. (1999) 2 74\(Suppl. 29)20064–20067.
   Google Scholar
• KHAN GR, MA H, HUANG R et al.: Inhibition of platelet adhesion by thrombostatin, a pan l activation inhibitor, in a model of arterial wall injury using balloon angioplasty. J. Am. Coll. Cardiol. (1999) 33 (Suppl. 2) :904–912.
   Google Scholar
• VERBEUREN TJ, SIMONET S, DESCOMBES J-J, COURCHAYC, CIMETIERE B, LAVIELLE G: S 31354 is a novel mixed tp-receptor antagonist and NO donor. Thromb. Haemost. (1999) Suppl. 1165 (Abstract).
   Google Scholar
• SANCHEZ EF, BUSH LR, SWENSON S, MARKLAND FS: Chimeric fibrolase: covalent attachment of an rgd-like peptide to create a potentially more effective thrombolytic agent. Throm. Res. (1997) 87 (Suppl. 3):289–302.
   Google Scholar
• WRIGHT DH, METTERS KM, ABRAMOVITS M, FORD HUTCHINSON AW: Characterization of the recombi-nant human prostanoid DP receptor and identifica-tion of L-644698, a novel selective DP agonist. Br. J. Pharmacol. (1998) 123 (Suppl. 7):1317–1324.
   Google Scholar
• TENG CM, WU CC, KO FN, LEE FY, KUO SC: YC-1, a nitricoxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur. Pharmacol. (1997) 320(2-3):161–166.
   PubMed Web of Science ®Google Scholar
• KUNAPULI SP, DANIEL JL: P2 receptor subtypes in thecardiovascular system. Biochem. J. (1998) 336\(Suppl. 3):513–523.
   Google Scholar
• KRONMAL RA, HART RG, MANOLIO TA, TALBERT RL, BEAUCHAMP NJ, NEWMAN A: Aspirin use and incident stroke in the cardiovascular health study. Stroke (1988) 29:887–894.
   Web of Science ®Google Scholar
• •Study suggests that aspirin therapy in low risk elderly patients is not effective for stroke prevention with women demonstrating a possible increased stroke incidence.
   Google Scholar
• STEERING COMMITTEE OF THE PHYSICIANS HEALTH STUDY RESEARCH GROUP: Final report on the aspirin component of the ongoing physicians' health study. N Engl. J. Med (1989) 321:129–135.
   PubMed Web of Science ®Google Scholar
• •In a relatively low-risk population, aspirin therapy reduced the incidence of MI but did not alter (? trend towards increase) stroke incidence.
   Google Scholar
• ISO H, HENNEKENS CH, STAMPFER MJ et al.: Prospectivestudy of aspirin use and risk of stroke in women. Stroke (1999) 3:1764–1771
   Web of Science ®Google Scholar
• LEVIN RI, HARPEL PC, WEIL D, CHANG TS, RIFKIN DB:Aspirin inhibits vascular plasminogen activator activity in vivo. studies utilizing a new assay to quantify plasminogen activator activity. J. Chn. Invest. (1984) 74:571–580.
   Google Scholar
• KELTON JG, HIRSH J, CARTER CJ, BUCHANAN MR: Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. J. Clin. Invest. (1978) 62:892–895.
   Google Scholar
• BEDNAR MM, GROSS CE, HOWARD DB, RUSSELL SR, THOMAS GR: Nitric oxide reverses aspirin antagonism oft-PA thrombolysis in a rabbit model of thromboem-bolic stroke. Exp. Neurol. (1997) 146:513–517.
   PubMed Web of Science ®Google Scholar
• •Suggests a possible interaction between aspirin and NO in vivo in acute stroke which may explain the discrepancy in clinical outcome for combination aspirin plus thrombolytics in stroke versus MI.
   Google Scholar
• BEDNAR MM, GROSS CE: Aspirin reduces cerebralblood flow in a rabbit model in vivo. Neuro Res. (1999) 21:488–490.
   Google Scholar
• AKAISHI Y, SAKUMA I, KUKAO M, KITABATAKE A: Combination of beraprost sodium and orally available prostacyclin analogue, with aspirin: a new promising anti-platelet prescription against stroke and athero-sclerosis? J. Am. Coll. Cardiol. (1998) 3 l\(Suppl. 2):352A.
   Google Scholar
• FIELDS WS, LEMAK NA, FRANKOWSKI RF, HARDY RJ:. Controlled trial of aspirin in cerebral ischemia. Stroke (1977) 8:301–314.
   Google Scholar
• •Of historical interest in defining the role of aspirin in secondary stroke prevention.
   Google Scholar
• ANTIPLATELET TRIALISTS' COLLABORATION: Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ (1988) 296:320–31.
   PubMed Web of Science ®Google Scholar
• •Seminal meta-analysis of the role of aspirin for stroke prevention in high risk patients.
   Google Scholar
• ANONYMOUS: ESPS 2. Primary endpoints. J. Neuro. Sci. (1997) 151:S13–S26.
   Google Scholar
• ••Pivotal study defining the additive benefit of aspirin plusdipyridamole for stroke prevention in a high risk population.
   Google Scholar
• HE J, WHELTON PK, VU B, KLAG MJ: Aspirin and risk ofhemorrhagic stroke. JAMA (1998) 280(22):1930–1935.
   PubMed Web of Science ®Google Scholar
• FARRELL B, GODWIN J, RICHARDS S, WARLOW C: TheUnited Kingdom transient ischemic attact (UK-TIA) aspirin trial: final results. J. Neurol. Neurosurg. Psychiatry (1991) 54:1044–1054.
   PubMed Web of Science ®Google Scholar
• ALBERS GW, HART RG, LUTSEP HL, NEWELL DW, SACCORL: Supplement to the guidelines for the management of transient ischemic attacks. Stroke (1 9 9 9) 30:2502-2511.
   Google Scholar
• Federal Register (1998) 63:56802–56819.
   Google Scholar
• CAPRIE STEERING COMMITTEE: A randomized, blinded,trial of clopidogrel versus aspirin in patients at risk of ischaemic events [see comments]. Lancet (1996) 348:1329–1339.
   PubMed Web of Science ®Google Scholar
• •Compares the two most commonly used antiplatelet therapies for secondary stroke prevention.
   Google Scholar
• HASS WK, EASTON JD, ADAMS HP et al.: A randomizedtrial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients [see comments]. N. Engl. J. Med. (1989) 321:501–507.
   PubMed Web of Science ®Google Scholar
• DE LA CRUZ JP, MATA JM, SANCHEZ DE LA CUESTA F:Triflusal vs. aspirin on the inhibition of human platelet and vascular cyclooxygenase. Genera/Pharma-cology (1992) 23 (Suppl. 2):297–300.
   Google Scholar
• MCNEELY W, GOA K: Triflusal. Drugs (1998) 55 (Suppl.6):823–835
   Google Scholar
• MATIAS-GUIU J, ALVARES-SABIN J, CODINA A: Compara-tive study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovas-cular disease. Revista de Neurologia (1 9 9 7) 25(147)1669–1672.
   Google Scholar
• KATO H, EMURA S, TAKEUCHI N et al. Treatment of branch retinal arterial occlusion with sodium ozagrel, a thromboxane a2 synthetase inhibitor. J. Int. Med. Research (1997) 25 (Suppl 2):108–111.
   PubMed Web of Science ®Google Scholar
• ITOH Y, YAMATANI K, OSHIDA N et al: clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery. No to Shinkei-Brain & Nerve(1998) 50\(Suppl. 2):147–155.
   Google Scholar
• KAMINOGO M, YONEKURA M, ONIZUKA M, YASUNAGA A, SHIBATA S: Combination of serine protease inhibitor fut-175 and thromboxane synthetase inhibitor oky-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage. Neurologia Medico-Chirurgica(1998) 38\(Suppl. 11)704–708.
   Google Scholar
• TRANSCHESI B, PILEGGI F, VERCAMMEN E: Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin. Eur. Heart.) (1994) 15:660–664.
   PubMed Web of Science ®Google Scholar
• VAN KOOTEN F, CIABATTONI G, KOUDSTAAL PJ, GROBBEE DE, KLUFT C, PATRONO C: Increased thromboxane biosynthesis is associated with poststroke dementia. Stroke (1999) 30:1542–1547.
   PubMed Web of Science ®Google Scholar
• HART RG: Increased risk of intracranial hemorrhagewhen aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc. Dis. (1999) 9:215–217.
   PubMed Web of Science ®Google Scholar
• DEL ZOPPO GJ, HIGASHIDA RT, FURLAN AJ, PESSIN MS, ROWLEY HA, GENT M: PROACT: A Phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke (1998) 29:4–11.
   PubMed Web of Science ®Google Scholar
• FURLAN A, HIGASHIDA R, WECHSLER L et al: Intra-arterial prourokinase for acute ischemic stroke. JAMA (1999) 282\(Suppl. 20:2003–2011.
   Google Scholar
• BEDNAR MM, QUILLEY J, THOMAS GR et al.: The effect of oral antiplatelet agents on t-PA-mediated thrombolysis in a rabbit model of thromboembolic stroke. Neurosurgery (1996) 39:352–359.
   PubMed Web of Science ®Google Scholar
• THOMAS GR, THIBODEAUX H, ERRETT CJ, BEDNAR MM, GROSS CE, BENNETT WF: Intravenous aspirin causes a paradoxical attenuation of cerebrovascular thrombolysis. Stroke (1995) 26:1039–1046.
   PubMed Web of Science ®Google Scholar
• BEDNAR MM, RAYMOND-RUSSELL SJ, BOOTH CL, GROSS CE: Combination tissue plasminogen activator and ticlopidine therapy in a rabbit model of acute thromboembolic stroke. Neurol. Res. (1996) 18:45–48.
   PubMed Web of Science ®Google Scholar
• TOAST INVESTIGATORS: Low molecular weight heparinoid, ORG 10172 (danaparoid) and outcome after acute ischemic stroke. JAMA (1998) 279:1265–1272.
   PubMed Web of Science ®Google Scholar
• GRYGLEWSKI RJ: Interactions between endothelial secretogogues. Ann. Med. (1995) 27:421–427.
   PubMed Web of Science ®Google Scholar
• GRYGLEWSKI RJ: Interactions between nitric oxide and prostacyclin. Semin. Thromb. HemosL (1993) 19:158–166.
   PubMed Web of Science ®Google Scholar
• VANE JR, BOTTING RM: Formation by the endothelium of prostacyclin, nitric oxide and endothelin. J. Lipid Merl. (1993) 6:395–404.
   PubMed Web of Science ®Google Scholar
• ADGEY AAJ: An overview of the results of clinical trials with glycoproteinllb/111a inhibitors. Eur. Heart J. (1998) 19(Suppl. D):D10–D21.
   Google Scholar
• FERGUSON JJ, TAQI K: Ilb/IIIa receptor blockade in acute myocardial infarction. Am. Heart J. (1999) 138 (Suppl. 2): S164–S170.
   Google Scholar
• KEREIKES DJ, BRODERICK TM, ROTH EM et al.: Time course, magnitude and consistency of platelet inhibi-tion by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percuta-neous coronary intervention. Am. J. Cardiol. (1999) 84\(Suppl. 4):391–395.
   Google Scholar
• INGALL AH, DIXON J, BAILEY A et al.: Antagonists of the platelet P2T receptor: a novel approach to antithrom-botic therapy. J. Merl. Chem. (1999) 42 (Suppl. 2):213–220.
   Google Scholar
• GORELICK PB, BORN GVR, D'AGOSTINO RB, HANLEY DF, MOYE L, PEPINE CJ: Therapeutic benefit, aspirin revisited in light of the introduction of clopidogrel. Stroke (1999) 30:1716–1721.
   PubMed Web of Science ®Google Scholar
• SIVENIUS J, CUNHA L, DIENER HC et al: Antiplatelet treatment does not reduce the severity of subsequent stroke. Neurology (1999) 53:825–829.
   PubMed Web of Science ®Google Scholar
• WAXMAN L SMITH DE, ARCURI KE, VALSUK GP: Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation Factor Xa. Science (1990) 248:593–596.
   PubMed Web of Science ®Google Scholar
• GIRARD TJ, MACPHAIL LA, LIKERT KM, NOVOTNY WF, MILETICH JP, BROZE GJ: Inhibition of Factor VIIa-tissue factor coagulation activity by a hybrid protein. Science (1990) 248:1421–1424.
   PubMed Web of Science ®Google Scholar
• TURPIE, AG: Successors to heparin: new antithrom-botic agents. Am. Heart (1997) 134:S71–S77.
   PubMed Web of Science ®Google Scholar
• ADRIE C, BLOCK KD, MORENO PR et al.: Inhaled nitric oxide increases coronary artery patency after thrombolysis. Circulation (1996) 94:1919–1926.
   PubMed Web of Science ®Google Scholar
• THOMAS JE, ROSENWASSER RH, ARMONDA RA et al.: Safety of intrathecal sodium nitroprusside for the treatment and prevention of refractory cerebral vasospasm and ischemia in humans. Stroke (1999) 30:1409–1416.
   PubMed Web of Science ®Google Scholar
• CLARK WM, WISSMAN S, ALBERTS GW, JHAMANDAS JH, MADDEN KP, HAMILTON S: Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. JAMA (1999) 282\(Suppl. 20:2019–2026.
   Google Scholar
• FASSBENDER K, DEMPFLE CE, MIELKE 0 et al.: Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke (1999) 30:2101–2104.
   Google Scholar
• BEDNAR MM, GROSS CE, RUSSELL SR, SHORT D, GICLAS PC: Activation of complement by tissue plasminogen activator, but not by acute cerebral ischemia, in a rabbit model of thromboembolic stroke. J. Neurosurg. (1997) 86:139–142
   PubMed Web of Science ®Google Scholar
• GURWITZ D, CUNNINGHAM DD: Neurite outgrowth activity of protease nexin-1 on neuroblastoma cells requires thrombin inhibition. J. Cell Physiol. (1990) 142:155–162.
   PubMed Web of Science ®Google Scholar
• DONOVAN FM, PIKE CJ, COTMAN CW, CUNNINGHAM DD: Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. J. Neurosci. (1997) 17:5316-5326. Martin M Bednar
   Google Scholar